Immunopathogenesis of HTLV-I-associated myelopathy/tropical spastic paraparesis

References

• Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, - Amitani H, et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia-like cells. Ann Neurol 1987; 21: 117–22.
   PubMed Web of Science ®Google Scholar
• Gessain A, Gout 0. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1992; 117: 933–46.
   PubMed Web of Science ®Google Scholar
• Höllsberg P, Hafler DA. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med 1993; 328: 1173–82.
   PubMed Web of Science ®Google Scholar
• Gessain A, Barin F, Vernant JC, Gout 0, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; ii: 407–9.
   Google Scholar
• Rodgers-Johnson P, Gajdusek DC, Morgan OS, Zaninovic V, Sarin PS, Graham DS. HTLV-I and HTLV-III antibodies and tropical spastic paraparesis. Lancet 1985; ii: 1247–8.
   Google Scholar
• Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; i: 1031–2.
   Google Scholar
• Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Blattner WA, ed. Human retrovirology: HTLV. New York, NY: Raven Press, 1990: 191–7.
   Google Scholar
• Akizuki S, Nakazato 0, Higuchi Y, Tanabe K, Setoguchi M, Yoshida S, et al. Necropsy findings in HTLV-I associated myelopathy. Lancet 1987; i: 156–7.
   Google Scholar
• Iwasaki Y. Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP). J Neurol Sci 1990; 96: 103–23.
   Google Scholar
• Yoshida M, Osame M, Kawai H, Toita M, Kuwasaki N, Nishida Y, et al. Increased replication of HTLV-I in HTLV-I-associated myelopathy. Ann Neurol 1989; 26: 331–5.
   PubMed Web of Science ®Google Scholar
• Gessain A, Saal F, Gout 0, Daniel MT, Flandrin G, de The G, et al. High human T-cell lymphotropic virus type I proviral DNA load with polyclonal integration in peripheral blood mononuclear cells of French West Indian, Guianese, and African patients with tropical spastic paraparesis. Blood 1990; 75: 428–33.
   PubMed Web of Science ®Google Scholar
• Nagasato K, Nakamura T, Shirabe S, Shibayama K, Ohishi K, Ichinose K, et al. Presence of serum anti-human T-lymphotropic virus type I (HTLV-I) IgM antibodies means persistent active replication of HTLV-I in HTLV-I-associated myelopathy. J Neurol Sci 1991; 103: 203–8.
   Google Scholar
• Kira J, Koyanagi Y, Yamada T, Itoyama Y, Goto I, Yamamoto N, et al. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. Ann Neurol 1991; 29: 194–201.
   PubMed Web of Science ®Google Scholar
• Nagai M, Usuku K, Matsumoto W, Komada D, Takenouchi N, Moritoyo T, et at. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/ TSP. J Neurovirol 1998; 4: 586–93.
   Google Scholar
• Furukawa Y, Fujisawa J, Osame M, Toita M, Sonoda S, Kubota R, et at. Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP). Blood 1992; 80: 1012–6.
   PubMed Web of Science ®Google Scholar
• Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995; 69: 2863–8.
   PubMed Web of Science ®Google Scholar
• Cavrois M, Leclercq I, Gout 0, Gessain A, Wain-Hobson S, Wattel E. Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated mye-lopathy. Oncogene 1998; 17: 77–82.
   PubMedGoogle Scholar
• Nagasato K, Nakamura T, Ohishi K, Shibayama K, Motomura M, Ichinose K, et at. Active production of anti-human T-lymphotropic virus type I (HTLV-I) IgM antibody in HTLV-I-associated myelopathy. J Neuroimmunol 1991; 32: 105–9.
   Google Scholar
• Kira J, Nakamura M, Sawada T, Koyanagi Y, Ohori N, Itoyama Y, et al. Antibody titers to HTLV-I-p40'" protein and gag-env hybrid protein in HTLV-I-associated myelo-pathy/tropical spastic paraparesis: correlation with in-creased HTLV-I proviral DNA load. J Neurol Sci 1992; 107: 98–104.
   Google Scholar
• Shattock RJ, Griffin GE. Cellular adherence enhances HIV replication in monocytic cells. Res Virol 1994; 145: 139–45.
   Google Scholar
• Guyot DJ, Newbound GC, Lairmore MD. Signaling via the CD2 receptor enhances HTLV-1 replication in T lympho-cytes. Virology 1997; 234: 123–9.
   Google Scholar
• Jacobson S, Shida H, McFarlin DE, Fauchi AS, Koenig S. Circulating CD8* cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990; 38: 245–8.
   Google Scholar
• Jacobson S, McFarlin DE, Robinson S, Voskuhl R, Martin R, Brewah A, et al. HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease. Ann Neurol 1992; 32: 651–7.
   Google Scholar
• Umehara F, Izumo S, Nakagawa M, Ronquillo AT, Takahashi K, Matsumuro K, et at. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1993; 52: 424–30.
   Google Scholar
• Levin MC, Lehky TJ, Flerlage AN, Katz D, Kingma DW, Jaffe ES, et al. Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type I-associated neurologic disease. N Engl J Med 1997; 336: 839–45.
   PubMedGoogle Scholar
• Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in per-ipheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detec-tion. J Immunol 1998; 161: 482–8.
   PubMed Web of Science ®Google Scholar
• Bangham CRM, Hall SE, Jeffery KJM, Vine AM, Witkover A, Nowak MA, et at. Genetic control and dynamics of the cellular immune response to the human T-cell leukemia virus, HTLV-I. Phil Trans R Soc Lond B 1999; 354: 691–700.
   Google Scholar
• Niewiesk S, Daenke S, Parker CE, Taylor G, Weber J, Nightingale S, et al. The transactivator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic para-paresis. J Virol 1994; 68: 6778–81.
   Google Scholar
• Koenig S, Woods RM, Brewah YA, Newell AJ, Jones GM, Boone E, et at. Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease. J Immunol 1993; 151: 3874–83.
   PubMed Web of Science ®Google Scholar
• Jeffery KJM, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, et at. HLA alleles determine human T-Iympho-tropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A 1999; 96: 3848–53.
   PubMed Web of Science ®Google Scholar
• Lehky TJ, Fox CH, Koenig S, Levin MC, Flerlage N, Izumo S, et at. Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol 1995; 37: 167–75.
   PubMed Web of Science ®Google Scholar
• Hara H, Morita M, Iwaki T, Hatase T, Itoyama Y, Kitamoto T, et at. Detection of human T lymphotropic virus type I (HTLV-I) proviral DNA and analysis of T cell receptor V beta CDR3 sequences in spinal cord lesions of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Exp Med 1994; 180: 831–9.
   Google Scholar
• Moritoyo T, Reinhart TA, Moritoyo H, Sato E, Izumo S, Osame M, et al. Human T-lymphotropic virus type I-associated myelopathy and tax gene expression in CD4+ T lymphocytes. Ann Neurol 1996; 40: 84–90.
   PubMedGoogle Scholar
• Matsuoka E, Takenouchi N, Hashimoto K, Kashio N, Moritoyo T, Higuchi I, et al. Perivascular T cells are infected with HTLV-I in the spinal cord lesions with HTLV-I-associated myelopathy/tropical spastic paraparesis: double staining of immunohistochemistry and polymerase chain reaction in situ hybridization. Acta Neuropathol 1998; 96: 340–6.
   PubMed Web of Science ®Google Scholar
• Kira J, Itoyama Y, Koyanagi Y, Tateishi J, Kishikawa M, Akizuki S, et al. Presence of HTLV-I proviral DNA in central nervous system of patients with HTLV-I-associated mye-lopathy. Ann Neurol 1992; 31: 39–45.
   PubMedGoogle Scholar
• Kuroda Y, Matsui M, Kikuchi M, Kurohara K, Endo C, Yukitake M, et at. In situ demonstration of the HTLV-I genome in the spinal cord of a patient with HTLV-I-associated myelopathy. Neurology 1994; 44: 2295–9.
   Google Scholar
• Levin MC, Jacobson S. Cellular and humoral responses associated with HTLV-I associated myelopathy/tropical spastic paraparesis. Ann N Y Acad Sci 1997; 835: 142–52.
   Google Scholar
• Levin MC, Krichavsky M, Berk J, Foley S, Rosenfeld M, Dalmau J, et al. Neuronal molecular mimicry in immune-mediated neurologic disease. Ann Neurol 1998; 44: 87–98.
   PubMed Web of Science ®Google Scholar
• Usuku K, Sonoda S, Osame M, Yashiki S, Takahashi K, Matsumoto M, et at. HLA haplotype-linked high immune .responsiveness against HTLV-I in HTLV-I-associated mye-lopathy: comparison with adult T-cell leukemia /lymphoma. Ann Neurol 1988; 23(Suppl): S143–50.
   Google Scholar
• Kitze B, Usuku K, Yashiki S, Ijichi 5, Fujiyoshi T, Nakamura M, et at. Intrathecal humoral immune response in HAM/ TSP in relation to HLA haplotype analysis. Acta Neurol Scand 1996; 94: 287–93.
   Google Scholar
• Usuku K, Nishizawa M, Matsuki K, Tokunaga K, Takahashi K, Eiraku N, et al. Association of a particular amino acid sequence of the HLA-DR betal chain with HTLV-I-associ-ated myelopathy. Eur J Immunol 1990; 20: 1603–6.
   PubMed Web of Science ®Google Scholar
• Sonoda S, Fujiyoshi T, Yashiki S. Immunogenetics of HTLV-I/II and associated diseases. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: S119–23.
   Google Scholar
• Yamano Y, Kitze B, Yashiki S, Usuku K, Fujiyoshi T, Kaminagayoshi T, et al. Preferential recognition of synthetic peptides from HTLV-I gp21 envelope protein by HLA-DRB1 alleles associated with HAM/TSP (HTLV-I-associated mye-lopathy/tropical spastic paraparesis). J Neuroimmunol 1997; 76: 50–60.
   PubMedGoogle Scholar
• Umehara F, Nakamura A, Izumo S, Kubota R, Ijichi S, Kashio N, et at. Apoptosis of T lymphocytes in the spinal cord lesions in HTLV-I-associated myelopathy: a possible mechanism to control viral infection in the central nervous system. J Neuropathol Exp Neurol 1994; 53: 617–24.
   Google Scholar
• Ijichi S, Izumo S, Eiraku N, Machigashira K, Kubota R, Nagai M, et at. An autoaggressive process against bystander tissues in HTLV-I-infected individuals: a possible patho-mechanism of HAM/TSP. Med Hypotheses 1993; 41: 542–7.
   Google Scholar
• Endo K, Tsukamoto T. Experimental bystander encephalitis induced by immunization with HTLV-I-producing T cells in mice. Acta Neurol Scand 1997; 96: 106–13.
   Google Scholar
• Umehara F, Izumo S, Takeya M, Takahashi K, Sato E, Osame M. Expression of adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) in the spinal cord lesions in HTLV-I-associated myelopathy. Acta Neuropathol 1996; 91: 343–50.
   PubMed Web of Science ®Google Scholar
• Umehara F, Okada Y, Fujimoto N, Abe M, Izumo S, Osame M. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in HTLV-I-associated mye-lopathy. J Neuropathol Exp Neurol 1998; 57: 839–49.
   PubMed Web of Science ®Google Scholar
• Kambara C, Nakamura T, Furuya T, Migita K, Ida H, Kawakami A, et al. Vascular cell adhesion molecule-1-mediated matrix metalloproteinase-2 induction in peripheral blood T cells is up-regulated in patients with HTLV-I-associated myelopathy. J Neuroimmunol 1999; 99: 242–7.
   Google Scholar
• Nakamura T, Furuya T, Nishiura Y, Ichinose K, Shirabe S, Eguchi K. Importance of immune deviation toward Thl in the early immunopathogenesis of human T-lymphotropic virus type I-associated myelopathy. Med Hypotheses 2000; 54: 777–82.
   PubMed Web of Science ®Google Scholar
• Ichinose K, Nakamura T, Kawakami A, Eguchi K, Nagasato K, Shibayama K, et al. Increased adherence of T cells to human endothelial cells in patients with human T-cell lymphotropic virus type I-associated myelopathy. Arch Neurol 1992; 49: 74–6.
   PubMed Web of Science ®Google Scholar
• Ichinose K, Nakamura T, Nishiura Y, Nagasato K, Ohishi K, Watanabe H, et al. Characterization of adherent T cells to human endothelial cells in patients with HTLV-I-associated myelopathy. J Neurol Sci 1994; 122: 204–9.
   Google Scholar
• Furuya T, Nakamura T, Shirabe S, Nishiura Y, Tsujino A, Goto H, et al. Heightened transmigrating activity of CD4-positive T cells through reconstituted basement membrane in patients with human T-lymphotropic virus type I-associated myelopathy. Proc Assoc Am Physicians 1997; 109: 228–36.
   Google Scholar
• Nishiura Y, Nakamura T, Ichinose K, Shirabe S, Tsujino A, Goto H, et at. Increased production of inflammatory cytokines in cultured CD4* cells from patients with HTLV-I-associated myelopathy. Tohoku J Exp Med 1996; 179: 227–33.
   PubMed Web of Science ®Google Scholar
• Furuya T, Nakamura T, Fujimoto T, Nakane S, Kambara C, Shirabe S, et at. Elevated levels of interleukin-12 and interferon-gamma in patients with human T lymphotropic virus type I-associated myelopathy. J Neuroimmunol 1999; 95: 185–9.
   Google Scholar
• Rieckmann P, Weber F, Gunther A, Martin S, Bitsch A, Broocks A, et at. Pentoxifylline, a phosphodiesterase inhibi-tor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996; 64: 193–200.
   PubMed Web of Science ®Google Scholar
• Shirabe S, Nakamura T, Tsujino A, Nishiura Y, Furuya T, Goto H, et al. Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci 1997; 151: 97–101.
   Google Scholar
• Fujimoto T, Nakamura T, Furuya T, Nakane S, Shirabe S, Kambara C, et al. Relationship between the clinical efficacy of pentoxifylline treatment and elevation of serum T helper type 2 cytokine levels in patients with human T-lymphotropic virus type I-associated myelopathy. Intern Med 1999; 38: 717–21.
   PubMed Web of Science ®Google Scholar
• Vernant J-C, Buisson G, Magdeleine J, De Thore J, Jouannelle A, Neisson-Vernant C, et at. T-Iymphocyte alveolitis, tropical spastic paraparesis, and Sjögren syndrome. Lancet 1988; i: 177.
   Google Scholar
• Kitajima I, Maruyama I, Maruyama Y, Ijichi S, Eiraku N, Mimura Y, et al. Polyarthritis in human T-lymphotropic virus type I-associated myelopathy. Arthritis Rheum 1989; 32: 1342–4.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Nakashima H, Watanabe S, Uyama E, Tanaka F, Ando M, et al. T-lymphotropic alveolitis in HTLV-I-associated myelopathy. Lancet 1987; ii: 1220.
   Google Scholar
• Sasaki K, Morooka I, Inomata H, Kashio N, Akamine T, Osame M. Retinal vasculitis in human T-Iymphotropic virus type I associated myelopathy. Br J Ophthalmol 1989; 73: 812–5.
   PubMedGoogle Scholar
• Nomata K, Nakamura T, Suzu H, Yushita Y, Kanetake H, Sawada T, et al. Novel complications with HTLV-I-associated myelopathy/tropical spastic paraparesis: interstitial cystitis and persistent prostatitis. Jpn J Cancer Res 1992; 83: 601–8.
   Google Scholar
• Nakamura H, Eguchi K, Nakamura T, Mizokami A, Shirabe S, Kawakami A, et al. High prevalence of Sjögren's syndrome in patients with HTLV-I-associated myelopathy. Ann Rheumatic Dis 1997; 56: 167–72.
   PubMed Web of Science ®Google Scholar
• Furuya T, Nakamura T, Goto H, Shirabe S, Nomata K, Kitaoka T, et at. HTLV-I-associated myelopathy associated with multi-organ inflammatory disease: a case report. J Neurol Sci 1998; 157: 109–12.
   Google Scholar
• Izumo S, Usuku K, Osame M, Machigashira K, Johnosono M, Nakagawa MThe neuropathology of HTLV-I-associated myelopathy in Japan: report of an autopsy case and review of the literature. In: Roman GC, Vernant J-C, Osame M, eds. HTLV-I and the nervous system. New York, NY: Alan R Liss; 1989: 261–7.
   Google Scholar
• Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996 ; 46: 1016–21.
   PubMed Web of Science ®Google Scholar
• Lehky TJ, Levin MC, Kubota R, Bamford RN, Flerlage AN, Soldan SS, et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated mye-lopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 1998; 44: 942–7.
   PubMed Web of Science ®Google Scholar
• Taylor GP, Hall SE, Navarrete S, Michie CA, Davis R, Witkover AD, et at. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-I-associated myelopathy. J Virol 1999; 73: 10289–95.
   PubMed Web of Science ®Google Scholar